Nivolumab plus ipilimumab in advanced melanoma.

PubWeight™: 17.53‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMID 23724867)

Published in N Engl J Med on June 02, 2013


Jedd D Wolchok1, Harriet Kluger, Margaret K Callahan, Michael A Postow, Naiyer A Rizvi, Alexander M Lesokhin, Neil H Segal, Charlotte E Ariyan, Ruth-Ann Gordon, Kathleen Reed, Matthew M Burke, Anne Caldwell, Stephanie A Kronenberg, Blessing U Agunwamba, Xiaoling Zhang, Israel Lowy, Hector David Inzunza, William Feely, Christine E Horak, Quan Hong, Alan J Korman, Jon M Wigginton, Ashok Gupta, Mario Sznol

Author Affiliations

1: Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Associated clinical trials:

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | NCT01024231

Articles citing this

(truncated to the top 100)

Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (2016) 5.79

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34

Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10

Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2013) 3.74

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell (2015) 3.03

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol (2014) 2.78

Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 2.74

Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 2.71

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell (2015) 2.60

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41

Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol (2015) 2.38

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol (2015) 2.30

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res (2014) 2.27

Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25

Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Cancer Cell (2016) 2.24

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19

The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) (2015) 2.17

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16

In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature (2014) 2.05

C-reactive protein as a marker of melanoma progression. J Clin Oncol (2015) 2.00

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res (2014) 2.00

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res (2014) 2.00

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer (2014) 1.92

Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell (2014) 1.88

Zebrafish cancer: the state of the art and the path forward. Nat Rev Cancer (2013) 1.87

Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res (2015) 1.77

Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res (2014) 1.73

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther (2015) 1.73

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One (2015) 1.73

Overcoming T cell exhaustion in infection and cancer. Trends Immunol (2015) 1.72

Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol (2013) 1.70

The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. EMBO J (2015) 1.69

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep (2015) 1.67

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood (2013) 1.67

Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol (2015) 1.65

Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58

Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell (2014) 1.55

Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55

Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A (2015) 1.54

PD-1/PD-L1 inhibitors. Curr Opin Pharmacol (2015) 1.53

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol (2014) 1.53

What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A (2014) 1.52

A 20-year experience of hepatic resection for melanoma: is there an expanding role? J Am Coll Surg (2014) 1.51

Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol (2015) 1.50

Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50

Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res (2013) 1.47

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood (2015) 1.47

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol (2014) 1.47

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46

Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol (2015) 1.45

Combination checkpoint blockade--taking melanoma immunotherapy to the next level. N Engl J Med (2013) 1.45

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One (2016) 1.44

Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res (2014) 1.43

Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med (2014) 1.40

Retracted The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int (2015) 1.40

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol (2016) 1.39

Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res (2013) 1.39

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature (2017) 1.39

The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science (2014) 1.37

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Res (2014) 1.34

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med (2015) 1.33

Resistance to RAF inhibitors revisited. J Invest Dermatol (2013) 1.33

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer (2015) 1.32

Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med (2015) 1.32

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res (2015) 1.31

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology (2013) 1.29

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell (2015) 1.27

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol (2015) 1.27

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity. Cell (2015) 1.26

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A (2015) 1.26

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int (2015) 1.25

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer (2015) 1.25

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer (2015) 1.24

Therapeutic cancer vaccines. J Clin Invest (2015) 1.23

Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. J Clin Invest (2015) 1.22

Articles by these authors

Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14

Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40

Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15

Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet (2013) 3.83

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res (2007) 3.74

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 3.10

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06

A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.80

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol (2007) 2.67

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65

Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst (2005) 2.60

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44

Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37

MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc Natl Acad Sci U S A (2009) 2.37

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med (2003) 2.30

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24

Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23

Lung cancer: computerized quantification of tumor response--initial results. Radiology (2006) 2.23

Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res (2009) 2.13

Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun (2006) 2.09

Do mitochondria contribute to left ventricular non-compaction cardiomyopathy? New findings from myocardium of patients with left ventricular non-compaction cardiomyopathy. Mol Genet Metab (2013) 2.08

Advances in the systemic treatment of metastatic melanoma. Oncology (Williston Park) (2013) 2.05

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03

Craniocerebral maduromycosis. J Neurosurg Pediatr (2012) 2.01

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00

MicroRNA signatures differentiate melanoma subtypes. Cell Cycle (2011) 1.99

A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res (2010) 1.98

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol (2009) 1.90

Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: a single-center, randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol (2011) 1.85

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85

Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood (2010) 1.77

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res (2011) 1.76

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood (2008) 1.74

Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem (2009) 1.73

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol (2013) 1.73

Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol (2008) 1.69

ExpressYourself: A modular platform for processing and visualizing microarray data. Nucleic Acids Res (2003) 1.68

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63

Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res (2004) 1.63

Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions. Kidney Int (2013) 1.60

Islet filtration: a simple and rapid new purification procedure that avoids ficoll and improves islet mass and function. Transplantation (2002) 1.58

Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res (2007) 1.57

EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res (2006) 1.56

Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope (2009) 1.54

Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2006) 1.53

Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol (2003) 1.53

TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest (2007) 1.53

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res (2013) 1.51

Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res (2005) 1.51

Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice. J Immunol (2004) 1.50

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer (2006) 1.49

Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol (2007) 1.49

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 1.48

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer (2007) 1.48

Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther (2007) 1.48

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med (2009) 1.47

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem (2009) 1.47

IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol (2004) 1.46

Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol (2010) 1.45

CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood (2006) 1.45